All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

MetaVia Q3 net loss widens on higher R&D costs

By Reuters News


Overview

  • Biotechnology firm's Q3 net loss widened yr/yr on higher R&D and administrative expenses

  • Company reported positive interim Phase 1 data for DA-1726 in liver-related cardiometabolic diseases

  • MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer to lead clinical development


Outlook

  • MetaVia targets initiation of a 48-week Phase 2 study for DA-1726 in MetALD and ALD in H2 2027

  • Company expects full data from DA-1726 Phase 1 Parts 3A and 3B in Q1 2027

  • MetaVia plans to begin Phase 2a proof-of-concept study for vanoglipel in combination with resmetirom in H1 2027


Result Drivers

  • R&D SPENDING - Higher Q3 R&D expenses were mainly due to increased direct costs for DA-1726 product development

  • CLINICAL DATA - Positive interim Phase 1 data for DA-1726 showed reductions in liver fat, body weight, and uric acid, supporting further development in liver-related diseases


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Basic Share

$0.69


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for MetaVia Inc is $20.00, about 1,438.5% above its November 12 closing price of $1.30


Reuters Recommended Reads

  • Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs

  • Nov 12 - Relmada Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 12 - Assembly Biosciences Q3 net loss widens on increased R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.